Addition of interleukin-6 inhibition with tocilizumab to standard graft-versus-host disease prophylaxis after allogeneic stem-cell transplantation: a phase 1/2 trial

Overview of attention for article published in Lancet Oncology, November 2014

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news: 3 news outlets
blogs: 1 blog

twitter: 19 X users
facebook: 3 Facebook pages

Citations

dimensions_citation: 198 Dimensions

Readers on

mendeley: 114 Mendeley

Summary News Blogs X Facebook Dimensions citations

So far, Altmetric has seen 3 news stories from 3 outlets.

Tocilizumab protects against bone graft response

6 Minutes, 17 Nov 2014

Australian-led study shows rheumatoid arthritis drug is effective as an additional prophylaxis for leukaemia patients

Articles Addition of interleukin6 inhibition with tocilizumab to standard graftversushost disease prophylaxis after allogeneic stemcell transplantation a phase 12 trial

Bioportfolio, 15 Nov 2014

Interleukin 6 is the main detectable and dysregulated cytokine secreted after allogeneic SCT and its inhibition is a potential…

NEW HOPE FOR BONE MARROW TRANSPLANT PATIENTS

Health Canal, 14 Nov 2014

Clinical trials led by QIMR Berghofer Medical Research Institute and the Royal Brisbane and Women’s Hospital are set to change…

This page shows the most recent news stories that mention this research output.

Click here to find out how to access more activity.